Aerogen Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345»
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Evaluation of Inhaled Epoprostenol on Oxygenation in Patients with COVID-19 () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_2042;    
    Secondary outcomes include change in central venous pressure, progression to ECMO, ICU length of stay, change in pressor use, and in-hospital mortality. These outcomes will be analyzed utilizing descriptive statistics.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Comparison of fixed-dose and weight-based dose inhaled epoprostenol in adult acute respiratory distress syndrome patients () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_1854;    
    Secondary endpoints will compare the response rate at four hours, defined as ≥ 10% or ≥ 20% increase of PaO2/FiO2 from baseline, the PaO2/FiO2 ratio at hours: -4, -2, -1, baseline, 1, 2, 4, 8, 12, 16, 24, 36, 48, 60, and 72, and clinical outcomes of in-hospital mortality, hospital and ICU length of stay, and duration of mechanical ventilation. This study will be submitted to the Institutional Review Board for approval.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Use Of Inhaled Epoprostenol In A Patient With Massive Pulmonary Embolism () -  Oct 17, 2020 - Abstract #ASA2020ASA_853;    
    Inhaled forms of prostacyclin-prostanoids effectively treat pulmonary hypertension, but there is less convincing data about their use in massive pulmonary embolism (PE). Because medications like epoprostenol can reduce right ventricular (RV) work, improve pulmonary blood flow and lower pulmonary arterial pressures, patients with massive PE may benefit from their use.
  • ||||||||||  Doburan (dobutamine) / VHB Life Sciences, VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Anesthetic Management Of A Left Ventricular Mycotic Pseudoaneurysm () -  Oct 17, 2020 - Abstract #ASA2020ASA_632;    
    Postoperative course was complicated by biventricular dysfunction requiring inotropic support with epinephrine and dobutamine. Patient was discharged to a SNF on POD 10.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] SCLEROTHERAPY OR SCLERODISTRESS? ARDS CAUSED BY SCLEROSING AGENTS USED FOR ROUTINE ARTERO-VENOUS MALFORMATION (AVM) EMBOLIZATION () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_1581;    
    His past medical history was significant for HIV (Last CD4 of 278 on Triumeq), ESRD previously on hemodialysis now status post a renal transplant, hypertension...Given this severity, he was started on lung-protective strategy, paralyzed, placed prone, and given inhaled epoprostenol... Further studies are needed to determine the extent and prevalence of major complications involved with routinely used sclerosing agents, risk factors contributing to these if any, so as to enable patients and providers to make an informed decision.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Nebulized epoprostenol: an evaluation of use and patient outcomes () -  Oct 8, 2020 - Abstract #ASHP2020ASHP_331;    
    Nebulized epoprostenol was used primarily in mechanically ventilated patients. Continued use or conversion to nitric oxide remained necessary for some patients on mechanical ventilation while a smaller portion of the patients were able to be extubated or converted to a tracheostomy collar with the use of nebulized epoprostenol.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    Journal:  Inhaled Epoprostenol to Facilitate Safe Transport in Legionnaires' Disease. (Pubmed Central) -  Sep 26, 2020   
    With continued climate changes, Legionella and other pathogens are likely to be a continued threat. As such, optimizing oxygenation to allow for transport should continue to be a priority for critical care transport (CCT) services.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Thiamine Deficiency Causing High-Output Heart Failure with Concomitant Vasoreactive Pulmonary Arterial Hypertension: A Case Report (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_7190;    
    While thiamine deficiency has been known to cause pulmonary hypertension by increasing cardiac output and left-sided filling pressures, this is the first report of thiamine deficiency causing high-output heart failure with concomitant vasoreactive pulmonary arterial hypertension. Further studies are needed to understand the mechanisms by which thiamine deficiency causes reversible pulmonary vascular constriction.
  • ||||||||||  Doburan (dobutamine) / VHB Life Sciences, VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Intravenous Epoprostenol for Acute Right Ventricular Failure After Heart Transplantation (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_7180;    
    Use of Intravenous Epoprostenol for acute RV dysfunction/failure post-OHT has not been previously reported. Systemic Epoprostenol might be a potential treatment for patients with acute RV failure secondary to PAH post-OHT.
  • ||||||||||  prednisone / Generic mfg., VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Recurrence of E-Cigarette Vaping Acute Lung Injury (EVALI) with Resumption of Vaping (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6923;    
    He progressed to severe acute respiratory distress syndrome (ARDS) requiring lung-protective ventilation, sedation, paralysis, and inhaled epoprostenol...High-dose prednisone was initiated...In our case, it is likely that the patient's comorbidities contributed to his significant hospital course. To date, there are no case reports regarding EVALI in medically-complex patients.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Pulmonary Edema Following Naloxone Administration for Opioid Overdose: A Case Series (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6727;    
    Nine of ten patients required ICU admission, seven were intubated and mechanically-ventilated, four received inhaled epoprostenol for refractory hypoxemia, and one patient was supported with veno-venous extracorporeal membrane oxygenation (ECMO). In our experience, naloxone associated pulmonary edema, while ultimately a self-limited condition, is frequently life-threatening and can demand substantial critical care resources to manage.
  • ||||||||||  sildenafil / Generic mfg., VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] A Case of Clinical Tamponade Obscuring Acute Right Ventricular Failure and Pulmonary Hypertension (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_4630;    
    In this case, clinical tamponade coexisted with RV failure in the setting of acute pulmonary embolism. Without the judicious use of TTE, RHC, and chest CT angiography, RV failure and pulmonary hypertension from acute pulmonary embolism could have been missed, leading to rapid life-threatening clinical deterioration.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] A Single Center Study of ARDS Outcomes in Patients with Underlying Malignancy (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_4404;    
    This pilot study demonstrated trends that patients with ARDS and cancer have higher mortality than patients with ARDS without cancer even after careful consideration of demographic and potentially confounding variables. This work supports a larger retrospective study with more traditionally defined metrics for statistical significance.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Inhaled Epoprostenol Versus Inhaled Nitric Oxide for Refractory Hypoxemia in Acute Respiratory Distress Syndrome (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_4394;    
    There was no difference in in hospital mortality (48% for iNO vs. 56% iEPO [p=0.31]) or hospital length of stay (16.6 days ± 13.6 for iNO vs 22.1 days ± 17.6 for iEPO [p=0.21)]). CONCLUSIONS In patients with refractory hypoxemia due to ARDS, iEPO and iNO have similar effects on acute changes in oxygenation without a difference in in hospital mortality or hospital length of stay at our institution.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Hypoxia and Hyperinflation: A Management Strategy (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_4023;    
    He was treated with bronchodilators and started on inhaled epoprostenol (iEPO)... This case illustrates a novel and not yet described treatment approach to the management of hypoxemia seen in patients with hyperinflation and worsening VQ mismatch resulting from positive pressure ventilation in the setting of advanced emphysema and regional lobar hyperinflation.
  • ||||||||||  epinephrine / Generic mfg., VentaProst (epoprostenol inhalation) / Aerogen Pharma
    [VIRTUAL] Acute Hemodynamic Compromise Following Induction and Intubation; Is It the Ventilator or a Massive PE? (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_3386;    
    He was given two doses of 0.1mg epinephrine followed by a norephinephrine infusion...He couldn't be extubated due to high FiO2 requirement despite diuresis and trial of inhaled epoprostenol...Past medical history is essential for proper management of acute on chronic RV failure. Vasopressors and close MV management are critical for treatment.
  • ||||||||||  verapamil / Generic mfg.
    [VIRTUAL] Catastrophic Non-Cardiogenic Pulmonary Edema Secondary to Massive Verapamil Overdose and Treatment with Extracorporeal Membrane Oxygenation (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_3014;    
    Blood pressure was 87/40 mmHg on admission, and she was placed on infusions of Norepinephrine, Dobutamine and high dose insulin, and given activated charcoal and calcium gluconate...Upon arrival, her SpO2 was 83% on 100% FiO2, PEEP 18, and inhaled Epoprostenol, so the decision was made to place her on VV-ECMO...Our case represents the fatal refractory ARDS non-responsive to first-line management and is also the first case of CCB overdose reported in the literature treated with V-V ECMO. V-V ECMO might have substantial benefits in supportive treatment of ARDS due to severe CCB poisoning.
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    Trial initiation date:  Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide (clinicaltrials.gov) -  Jun 19, 2020   
    P=N/A,  N=108, Not yet recruiting, 
    V-V ECMO might have substantial benefits in supportive treatment of ARDS due to severe CCB poisoning. Initiation date: Feb 2020 --> Jul 2020
  • ||||||||||  AeroFact (AP-002) / Aerogen Pharma
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (clinicaltrials.gov) -  Mar 10, 2020   
    P2,  N=261, Recruiting, 
    Initiation date: Feb 2020 --> Jul 2020 Not yet recruiting --> Recruiting | Trial completion date: Apr 2020 --> Dec 2021 | Initiation date: Aug 2019 --> Mar 2020 | Trial primary completion date: Mar 2020 --> Dec 2020
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    Trial completion, Trial completion date:  Nebulized Epoprostenol (FLOLAN) and Phenylephrine on One Lung Ventilation (OLV) (clinicaltrials.gov) -  May 17, 2019   
    P4,  N=8, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2018
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  Nebulized Epoprostenol (FLOLAN) and Phenylephrine on One Lung Ventilation (OLV) (clinicaltrials.gov) -  May 4, 2018   
    P4,  N=10, Active, not recruiting, 
    Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Jun 2018 --> Jan 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Jun 2017
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    Enrollment change, Trial termination:  Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension (clinicaltrials.gov) -  Sep 16, 2016   
    P2,  N=3, Terminated, 
    Not yet recruiting --> Recruiting N=10 --> 3 | Recruiting --> Terminated; Difficulty with patient recruitment
  • ||||||||||  VentaProst (epoprostenol inhalation) / Aerogen Pharma
    Trial primary completion date:  Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension (clinicaltrials.gov) -  Dec 17, 2014   
    P2,  N=10, Recruiting, 
    N=10 --> 3 | Recruiting --> Terminated; Difficulty with patient recruitment Trial primary completion date: Sep 2014 --> Sep 2016